ClarityVesting

Sign in Get free access

Healthcare

Stock Analysis · Smith & Nephew plc (SNNUF)

Smith & Nephew makes orthopedic implants, sports medicine devices, and advanced wound care products. Demand is supported by aging populations and procedure growth, while stronger margins and cash flow have made the business notably more resilient.

Stock Analysis · Solventum Corp (SOLV)

Solventum is a newly independent healthcare supplier with established positions in medical consumables, dental products, healthcare software, and filtration. Strong margins and broad product breadth make it a company worth a closer look.

Stock Analysis · Revvity Inc (RVTY)

Revvity provides diagnostics and life science tools used in testing and research. The business has regained modest growth after a post-pandemic reset, supported by recurring consumables revenue, specialized niches, and improving cash generation.

Stock Analysis · Repligen Corporation (RGEN)

Repligen supplies the filtration, chromatography, analytics, and protein tools used to manufacture biologic drugs. Sales are recovering, cash flow remains solid, and its niche positions are attractive, making the company a close look in a growing part of healthcare.

Stock Analysis · Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics is a peptide-drug biotech with a strong balance sheet, major partnership validation, and rising visibility around rusfertide. The appeal lies in meaningful clinical upside and platform credibility, even though results remain uneven and event-driven.

Stock Analysis · Qiagen NV (QGEN)

Qiagen provides molecular testing and genomics workflow tools used in labs and clinical settings. High margins, recurring consumables revenue, and solid cash generation make it a strong-quality business, with future upside tied to better growth in diagnostics and automation.

Stock Analysis · Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines is a neuroscience biotech developing targeted treatments for essential tremor, epilepsy, and related brain disorders. Its appeal rests on late-stage pipeline potential, focused R&D strategy, and a debt-light balance sheet.